coronary slow flow phenomenon
Conditions
Interventions
Alprostadil group:Oral alprostadil (40 µg/tablet, three times per day)
isosorbide dinitrate group:isosorbide dinitrate (5 mg/tablet, three times per day)
Sponsors
Shanghai Chest Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: i) angiographically normal or near-normal (less than 30% stenosis) in any of the three major epicardial coronary arteries; ii) delayed opacification in at least one of the major coronary arteries. CSFP was assessed using Thrombolysis In Myocardial Infarction (TIMI) flow grade, defining as TIMI-2 (requiring over three beats to opacify the distal artery).
Exclusion criteria
Exclusion criteria: i) contraindication of alprostadil administration; ii) past history of myocardial infarction or percutaneous coronary intervention; iii) left ventricular systolic dysfunction (left ejection fraction less than 50%); iv) sinus node disease, conduction block, frequent atrial or ventricular arrhythmia; v) other comorbidities with prognosis less than twelve months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of typical angina episodes per week;Pain intensity of angina episodes evaluated via a Likert-type scale, where 0 indicated ‘no pain’ and 10 indicated ‘worst pain imaginable’;Severity of angina episodes assessed by Canadian Cardiovascular Society (CCS) classification; | — |
Secondary
| Measure | Time frame |
|---|---|
| The Seattle Angina Questionnaire (SAQ); | — |
Countries
China
Contacts
Public ContactZhang Weifeng
Shanghai Chest Hospital
Outcome results
None listed